GSK To Return International Development And Sales Rights For EPO Biosimilar To JCR
This article was originally published in PharmAsia News
Executive Summary
Japan Chemical Research has agreed with GlaxoSmithKline that the British company will return international development and sales rights for the EPO formulation used for treatment of renal anemia back to the Japanese company.